Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the BIO CEO & Investor Digital Conference from February 16 to 18, 2021. Their pre-recorded presentation will be available on demand for registered attendees and will also be accessible on their website for 30 days post-event. The company is focused on developing CRV431, a drug candidate targeting non-alcoholic steatohepatitis (NASH) and liver disease. Hepion is utilizing its proprietary AI platform, AI-POWR, to enhance drug development and identify optimal patient responses.
- None.
- None.
EDISON, NJ / ACCESSWIRE / February 9, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, announced today that management will participate in the BIO CEO & Investor Digital Conference, which is being held February 16 - 18, 2021.
Hepion's pre-recorded presentation will be available on demand during the virtual event for all registered attendees. Beginning on Tuesday, February 16, 2021, the presentation will also be available for approximately 30 days on the Company's website at www.hepionpharma.com under "Events" in the Investors section.
About Hepion Pharmaceuticals
The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies.
Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.
For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com
SOURCE: Hepion Pharmaceuticals, Inc.
View source version on accesswire.com:
https://www.accesswire.com/628815/Hepion-Pharmaceuticals-to-Participate-in-BIO-CEO-Investor-Digital-Conference
FAQ
What dates will Hepion Pharmaceuticals participate in the BIO CEO & Investor Digital Conference?
Where can I watch Hepion's presentation from the BIO CEO & Investor Digital Conference?
What is CRV431 and how is it related to NASH?
What is the purpose of Hepion's AI platform, AI-POWR?
How does CRV431 affect liver disease according to preclinical studies?
